Bay Harbor Wealth Management’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.95K Buy
13
+7
+117% +$1.25K ﹤0.01% 555
2026
Q1
$1.03K Buy
6
+1
+20% +$185 ﹤0.01% 762
2025
Q4
$997 Buy
5
+2
+67% +$363 ﹤0.01% 642
2025
Q3
$469 Buy
3
+2
+200% +$318 ﹤0.01% 751
2025
Q2
$151 Buy
+1
New +$133 ﹤0.01% 1013

Other funds holding CRL

Bay Harbor Wealth Management's CRL Position: Q2 2026 in Review

Bay Harbor Wealth Management increased its Charles River Laboratories (CRL) stake by 117% in Q2 2026, buying an estimated $1.25K and bringing the position to 13 shares worth $2.95K. The position accounts for ﹤0.01% of the portfolio, ranked #555.

Bay Harbor Wealth Management first reported a position in CRL in Q2 2025 and has held it in 5 quarters since. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Bay Harbor Wealth Management held 13 shares of Charles River Laboratories worth $2.95K as of Q2 2026.
  • Bay Harbor Wealth Management bought 7 Charles River Laboratories shares in Q2 2026, an estimated $1.25K.
  • Charles River Laboratories made up ﹤0.01% of Bay Harbor Wealth Management's portfolio in Q2 2026, its #555 holding.
  • Bay Harbor Wealth Management first reported a position in Charles River Laboratories in Q2 2025 and has held it in 5 quarters since.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Bay Harbor Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.